Research suggests potential health benefits beyond what popular diabetes and weight-loss drugs were first approved to treat.

and Novo Nordisk revealed new data pointing to a “clinically meaningful” improvement in osteoarthritis patients’ pain and physical function in the STEP 9 trial.

G LP-1 drugs containing semaglutide (the active ingredient in Ozempic and Wegovy) have exploded in popularity for their ...

The US regulator is carrying out a standard 10-month review of tanezumab as a treatment for chronic pain due to moderate-to-severe osteoarthritis (OA) in those who can’t get sufficient pain ...

Novo Nordisk has officially begun building a $1.8 billion production ... for MOTYS, the company’s lead osteoarthritis biologic drug. The FDA also granted MOTYS Fast Track designation. "Securing RMAT ...

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

Novo Nordisk (NVO) faces a 6% premarket drop after clinical trial results for its obesity drug CagriSema fell below ...

Novo Nordisk (NVO) stock rebounds after Kepler Cheuvreux upgrades to Buy following a 42% stock drop over the past year. Read ...

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.

Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...